Monthly Archives: October 2016

 

puzz2-fw

Ask the Expert – The Problem with Puzzles

By Alzheimer’s Prevention Bulletin Our October expert is Deborah Blacker, MD, ScD, Professor of Psychiatry at Harvard Medical School and Professor and Deputy Chair, Epidemiology at the Harvard T.H. Chan School of Public Health. Dear Dr. Blacker, I understand that memory games and crossword puzzles are supposed to be good for your brain health. But […]
puzzles-fw

Engage Your Brain – Help Prevent Dementia – Alzheimer’s Prevention Bulletin

What’s a 10 Letter Word for Maintaining Your Brain? E-n-g-a-g-e-m-e-n-t For Deborah Blacker, MD, ScD, and her colleagues, brain health and dementia prevention is serious business, but they can sum up a portion of their recent research findings with a humorous anecdote. “A colleague of mine who worked on the study shared this, ‘A patient […]
pierre

Good News in Alzheimer’s!

Watch the recording as Dr. Pierre N. Tariot, Director of the Banner Alzheimer’s Institute, discusses the latest research into Alzheimer’s treatment and prevention. In this recording, he examines what we know about Alzheimer’s , including the role of genes in its development. He also talks about risk factors for the disease, important new studies currently […]
braint3-fw

T3D Boosts Cognition in Half of Alzheimer’s Patients

DRUG TRIAL VIDEO & ARTICLE: See how the investigational new drug, T3D-959, elicited rapid improvement in cognitive tests in 53% of subjects with Alzheimer’s. Look into the exploratory, open label Phase 2a study. In an open-label exploratory study, 36 subjects with mild to moderate disease (MMSE 14-26) were randomized to receive 1 of 4 doses […]
vtv-fw

vTv Therapeutics Completes Enrollment of Part A of Pivotal Phase 3 Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease

Phase 2b Trial Showed Positive Results In Slowing Cognitive Decline High Point, North Carolina (September 7, 2016) vTv Therapeutics Inc. (NASDAQ:VTVT) today announced the completion of enrollment for Part A of STEADFAST (Single Trial Evaluating Alzheimer’s Disease Following Addition to Symptomatic Therapy), vTv’s Phase 3 placebo-controlled trial of azeliragon, an oral antagonist of the Receptor […]